A New Retrospective Study Shows PuraBond Benefits in Adult Tonsillectomy

Tonsillectomy is one of the most common surgical procedures and accounts for 17% of elective...

Corporate and “Meet the experts” events: The winning strategy of 3-D Matrix

3-D Matrix continues to be focused on its events strategy with the aim of continuing to develop its...

First clinical study evaluating the use of PuraBond for the reduction of post-op haemorrhage and post-op complications in Transoral Robotic Surgery (TORS)

The use of Transoral Robotic surgery (TORS) is increasingly growing in Head and Neck and in Ear,...

3-D Matrix Summer Update

3-D Matrix would like to wish you all a wonderful summer and take this opportunity to remind you...

Notice regarding the Conclusion of an Agreement Concerning Manufacturing License with FUSO Pharmaceutical Industries, Ltd.

3-D Matrix, Ltd. (headquarters: Chiyoda-ku, Tokyo; President and Representative Director: Jun...

3-D Matrix keeps aiming in the ENT and Plastic Surgery medical areas with PuraBond

The 3-D Matrix agenda keeps being filled with a selection of events, including those dedicated to...

PuraStat becomes PuraBond for cardiac surgeons in Spain

In conjunction with its participation at the XXVI edition of the Secce’s congress in Oviedo, 3-D...

3-D Matrix ranked in the Top 500 Fastest Growing Companies in Asia-Pacific region published by Financial Times

We are pleased to share that 3-D Matrix has been ranked 179th on the list of the 500...

Prof Di Bartolomeo Chairs 3-D Matrix Cardiac Symposium

On Thursday 14th October 2021, 3-D Matrix hosted a hybrid symposium, ‘Haemostasis in Cardiac Surgery